Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Gross Profit Growth
18.69%
TTM · Period ending:
LCTX Gross Profit Growth
Year-over-year change vs the same period a year earlier
Latest reported18.69%period ending
Latest reported18.69%period ending
LCTX TTM Gross Profit YoY % (-33.33% → 18.69%)
Year-over-year change
High-resolution chart · PNG
LCTX gross profit growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | Gross Profit Growth |
|---|---|
| 18.6907% | |
| 55.9612% | |
| 60.2892% | |
| 33.3922% | |
| 102.0687% | |
| 32.586% | |
| 11.0014% | |
| -3.9007% | |
| -46.9973% | |
| -37.367% | |
| -42.0465% | |
| -36.0969% | |
| -12.5835% | |
| 52.1224% | |
| 465.7895% | |
| 631.4836% | |
| 1,341.3181% | |
| 1,378.8732% | |
| 536.5979% | |
| 68.9952% | |
| -13.1057% | |
| -51.6066% | |
| -63.6023% | |
| 119.5378% | |
| 50.8306% | |
| 7.0907% | |
| -4.3088% | |
| -68.4768% | |
| -64.4208% | |
| -38.8393% | |
| -31.4039% | |
| -18.2458% | |
| -4.2986% | |
| -13.0338% | |
| -11.835% | |
| 22.3989% | |
| 11.5457% | |
| 21.3324% | |
| 29.1319% | |
| 21.4311% | |
| 38.1502% | |
| 41.4291% | |
| 28.704% | |
| -35.4467% | |
| -41.4455% | |
| -49.6309% | |
| -46.4153% | |
| 38.6725% | |
| 4.4968% | |
| -15.9806% | |
| -24.8708% | |
| -65.5224% | |
| -56.5666% | |
| -39.4163% | |
| -36.1394% | |
| -1.7677% | |
| 13.9202% | |
| 9.6003% | |
| 17.0963% | |
| 36.0819% | |
| 43.3415% | |
| 56.0858% | |
| 91.2361% | |
| 106.1473% | |
| 83.46% | |
| 68.7582% | |
| 28.0208% | |
| -7.3511% | |
| 4.328% | |
| 20.1513% | |
| 43.7493% | |
| 35.0571% | |
| 11.9776% | |
| 1.3268% | |
| -9.9735% | |
| 29.1192% | |
| 45.4998% | |
| 22.2374% | |
| 28.6555% | |
| 3.6202% | |
| 5.6163% | |
| 27.3917% | |
| 31.207% | |
| 16.5137% | |
| 16.5794% | |
| 26.8008% | |
| 23.7147% | |
| 53.835% | |
| 48.7477% | |
| 38.483% | |
| 43.7711% | |
| 89.656% | |
| 123.2839% | |
| 141.6492% | |
| 154.7575% | |
| 50.2376% | |
| 34.7751% | |
| 23.9234% | |
| 18.7297% | |
| 82.5083% |